ENTPD1 and thyroid gland carcinoma: Like CD39, the expression of CD73 in the tumor microenvironment has been studied as a prognostic biomarker for clinical outcomes of a variety of tumor types, including squamous cell carcinoma of the lung, pheochromocytoma, pancreatic cancer, urothelial carcinoma of the bladder, esophageal carcinoma, gastric adenocarcinoma, thyroid carcinoma, and pleomorphic glioblastoma, with metastasis and shorter time to recurrence [68].